| 证券代码：603939 | 证券简称：益丰药房 | 公告编号：2025-050 | | --- | --- | --- | | 债券代码：113682 | 债券简称：益丰转债 | | 益丰大药房连锁股份有限公司 关于使用闲置募集资金委托理财到期赎回 并继续委托理财的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 本次赎回产品名称：共赢智信汇率挂钩人民币结构性存款 A02288 期 （6,000.00 万），点金系列看涨两层区间 39 天结构性存款（1,000.00 万）。 赎回金额：7,000.00 万元 本次继续委托理财金额：6,000.00 万元 已履行的审议程序：经公司第五届董事会第十五次会议审议通过，同意在 确保不变相改变募集资金用途与不影响募集资金投资项目正常运行的情况下，使 用最高额度不超过 30,000.00 万元募集资金进行委托理财，用于购买安全性高、 流动性好的理财产品，自董事会审议通过起 12 个月有效，在上述额度与有效期 限内，购买理财产品资金可循环滚动使用。 特别风险提示 ...

Core Insights - The AMAC Wholesale Retail Trade Index (AMAC批零, H11045) increased by 1.3%, closing at 1617.5 points with a trading volume of 31.254 billion [1] - Over the past month, the index has risen by 2.93%, by 1.85% over the last three months, and by 0.73% year-to-date [1] Index Composition - The AMAC Wholesale Retail Trade Index is based on 43 industry classification indices, excluding manufacturing, and is compiled according to the classification guidelines from the China Securities Association [1] - The top ten weighted stocks in the index are: Huadong Medicine (5.33%), Yonghui Supermarket (3.05%), Digital China (2.87%), Shanghai Pharmaceuticals (2.83%), Wancheng Group (2.26%), Wuchan Zhongda (2.21%), Yifeng Pharmacy (2.19%), Jiuzhoutong (1.83%), Sinopharm (1.58%), and Kidswant (1.57%) [1] Market Distribution - The market distribution of the AMAC Wholesale Retail Trade Index shows that the Shenzhen Stock Exchange accounts for 53.12%, while the Shanghai Stock Exchange accounts for 46.88% [1] Industry Breakdown - In terms of industry composition, discretionary consumption accounts for 36.90%, healthcare for 31.52%, industrials for 22.28%, staples for 4.58%, energy for 2.78%, real estate for 1.27%, and financials for 0.67% [2]

Group 1 - The annual shareholders' meeting of Yifeng Pharmacy Chain Co., Ltd. was held on May 29, 2025, in Changsha, Hunan Province [2] - The meeting was conducted in compliance with the Company Law and the company's articles of association, utilizing both on-site and online voting methods [2][3] - All current directors and supervisors attended the meeting, with a total of 9 directors and 3 supervisors present [3] Group 2 - All proposed resolutions were approved during the meeting, including the annual work reports of the board and supervisory committee, financial statements, and profit distribution plan for 2024 [4][5][6] - The meeting authorized the board to formulate a mid-term dividend plan and approved the appointment of an accounting firm for 2025 [5][6] - A significant resolution regarding the company's shareholder return plan for the next three years (2025-2027) was also passed [6] Group 3 - The meeting was witnessed by lawyers from Hunan Qiyuan Law Firm, confirming that the meeting's procedures and voting results were legally valid [6]

Core Viewpoint - The legal opinion confirms that the procedures for the 2024 annual shareholders' meeting of Yifeng Pharmacy Chain Co., Ltd. were conducted in accordance with relevant laws and regulations, ensuring the legitimacy of the meeting and its outcomes [1][4][6]. Group 1: Meeting Procedures - The notice for the shareholders' meeting was announced on the designated media platform, detailing the time, location, voting methods, and agenda [3]. - The meeting took place on May 29, 2025, at 14:00 in Changsha, with both on-site and online voting options available for shareholders [3][4]. Group 2: Attendance and Qualifications - A total of 18 shareholders and their proxies attended the meeting in person, representing 657,188,892 shares, which is 54.2049% of the total shares [4][5]. - An additional 324 shareholders participated through online voting, representing a significant portion of the total shares [4]. Group 3: Voting Procedures and Results - The meeting utilized a combination of on-site and online voting, with a rigorous process for counting and monitoring votes, ensuring transparency [5][6]. - All proposals presented at the meeting received over 95% approval from the valid voting shares, indicating strong support from shareholders [6]. Group 4: Conclusion - The legal opinion concludes that the meeting's procedures, attendance qualifications, and voting results were all conducted in compliance with applicable laws and the company's articles of association [6].

Meeting Details - The shareholders' meeting was held on May 29, 2025, at Yifeng Pharmaceutical Logistics Park, Changsha, Hunan [1] - The meeting had a total attendance of 77.729% of the shares [1] Voting Results - All resolutions presented at the meeting were approved with overwhelming support from shareholders, with the highest approval rate being 99.9935% for one of the proposals [2][3] - The voting method combined both on-site and online participation, ensuring compliance with legal and regulatory requirements [1][3] Legal Compliance - The meeting's procedures, including the qualifications of attendees and the voting process, were confirmed to be in accordance with the Company Law and the company's articles of association [3]

| 证券代码：603939 | 证券简称：益丰药房 | 公告编号：2025-049 | | --- | --- | --- | | 债券代码：113682 | 债券简称：益丰转债 | | 益丰大药房连锁股份有限公司 2024年年度股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 二、议案审议情况 本次会议是否有否决议案：无 一、会议召开和出席情况 (一) 股东会召开的时间：2025 年 5 月 29 日 (二) 股东会召开的地点：湖南省长沙市金洲大道 68 号益丰医药物流园三楼 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 342 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 942,399,960 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 77.7290 | (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本 ...

关于益丰大药房连锁股份有限公司 2024年年度股东会的 法律意见书 二O二五年五月 致：益丰大药房连锁股份有限公司 （三）本所律师未授权任何单位或个人对本法律意见书作任何解释或说明。 为发表本所律师见证意见，本所律师依法审核了公司提供的下列资料： 1、刊登在中国证券监督管理委员会（以下简称"中国证监会"）指定媒体巨 潮资讯站（http://www.cninfo.com.cn/）的与本次股东会有关的通知等公告事项； 2、出席会议的股东或其代理人的身份证明文件、持股证明文件、授权委托书 等； 湖南启元律师事务所（以下简称"本所"）接受益丰大药房连锁股份有限公 司（以下简称"公司"）的委托，指派律师出席了公司 2024 年年度股东会（以下 简称"本次股东会"），对本次股东会的召集和召开程序、出席会议人员及召集 人的资格、表决程序和表决结果的合法有效性进行现场律师见证，并发表本法律 意见。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》、《上市公司股东会规则》（以下简称"《股东会规则》"） 等我国现行法律、法规、规范性文件以及《益丰大药房连锁股份有限公司章程》 （以下简称" ...

Core Viewpoint - The China Securities Index for Food and Major Consumer Goods Retail has shown a decline in performance over various time frames, indicating potential challenges in the sector [1][2]. Group 1: Index Performance - The China Securities Index for Food and Major Consumer Goods Retail is currently at 9719.75 points, having decreased by 0.13% over the past month, 2.88% over the past three months, and 4.47% year-to-date [1]. - The index is based on a sample of listed companies in the food and drug retail sector, reflecting the overall performance of these securities [1]. Group 2: Index Composition - The top ten weighted companies in the index include Yonghui Supermarket (6.96%), Digital China (6.48%), Shanghai Pharmaceuticals (6.14%), Yifeng Pharmacy (4.97%), and others, indicating a concentration in a few key players [1]. - The index is primarily composed of companies listed on the Shanghai Stock Exchange (55.91%) and Shenzhen Stock Exchange (44.09%) [1]. Group 3: Industry Breakdown - The industry composition of the index shows that pharmaceutical commerce accounts for 48.65%, specialized retail for 19.84%, department stores for 16.99%, and supermarkets and convenience stores for 14.52% [2]. - The index samples are adjusted biannually, with changes implemented on the next trading day following the second Friday of June and December [2].

Core Viewpoint - The company, Yifeng Pharmacy Chain Co., Ltd., is set to hold an annual performance briefing for 2024 and the first quarter of 2025 on June 3, 2025, to provide insights into its operational results and financial status [2][3][4]. Group 1: Performance Briefing Details - The performance briefing will take place on June 3, 2025, from 15:00 to 16:00 [4]. - The event will be held at the Shanghai Stock Exchange Roadshow Center and will utilize video and online interaction for communication [4][5]. - Investors can submit questions for the briefing from May 27 to June 2, 2025, through the Roadshow Center website or via the company's email [2][5]. Group 2: Management Participation - Key participants in the briefing will include the Chairman and CEO, Mr. Gao Yi, the Financial Officer, Mr. Wang Yonghui, the Board Secretary, Mr. Fan Wei, and the Independent Director, Mr. Huang Chunan [4]. Group 3: Shareholding and Reduction Plan - Prior to the reduction plan, the Executive President, Mr. Gao Youcheng, held 201,600 shares, representing 0.0166% of the total share capital, while the Assistant President, Mr. Yan Jun, held 99,600 shares, representing 0.0082% [8]. - The reduction plan was disclosed on January 24, 2025, with a maximum reduction of 75,300 shares planned, which was successfully executed within the specified timeframe [9][10].

| 证券代码：603939 | 证券简称：益丰药房 | 公告编号：2025-048 | | --- | --- | --- | | 债券代码：113682 | 债券简称：益丰转债 | | 益丰大药房连锁股份有限公司 高级管理人员减持计划时间届满暨 减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 高级管理人员的基本情况 本次减持股份计划实施前，益丰大药房连锁股份有限公司（以下简称"公司"） 执行总裁高佑成先生持有公司股份 201,600 股（全部为无限售流通股），占公司 总股本比例0.0166%；公司助理总裁颜俊先生持有公司股份99,600股（其中16,200 股为有限售流通股，83,400 股无限售流通股），占公司总股本比例 0.0082%。上 述股份来源均为限制性股票激励计划授予及资本公积金转增股本取得。 减持计划的实施结果情况 1 | 股东身份 | 控股股东、实控人及一致行动人 | | □是 | √否 | | --- | --- | --- | --- | --- | | | 直 ...